Dogwood Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses

Accrued Expenses

6 Months Ended

Jun. 30, 2022

Accrued Expenses

Accrued Expenses

5Accrued Expenses

Accrued expenses consist of the following:


		June 30,			December 31,
		2022			2021
Accrued compensation		$	346,496		$	532,678
Accrued interest on preferred members’ interests			188,085			188,085
Accrued clinical research costs			667,321			138,522
Accrued director fees			—			31,000
Accrued professional fees			17,800			24,100
Other miscellaneous accrued expenses			12,491			7,375
		$	1,232,193		$	921,760